Skip to main content

Advertisement

SpringerLink
Log in

Public biotech in 2016—the numbers

  • Feature
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

The anticipated decline in the biotech industry's ability to raise capital from public investors and an accompanying slump in biotech markets materialized in 2016, but all is not gloom and doom.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: NASDAQ biotech index over time.
Figure 2
Figure 3: Global biotech industry financing.
Figure 4: Public biotech barometers.
Figure 5

References

  1. Senior, M. Billion-dollar deals end eras of Ariad and Actelion. Nat. Biotechnol. 35, 183–184 (2017).

    Article  CAS  Google Scholar 

  2. Lawrence, S. Biotech's wellspring-a survey of the health of the private sector in 2016. Nat. Biotechnol. 35, 413–420 (2017).

    Article  CAS  Google Scholar 

  3. Morrison, C. Fresh from the biotech pipeline—2016. Nat. Biotechnol. 35, 108–112 (2017).

    Article  CAS  Google Scholar 

  4. Levin, J.M. et al. US immigration order strikes against biotech. Nat. Biotechnol. 35, 204–206 (2017).

    Article  CAS  Google Scholar 

  5. Garber, K. Alnylam terminates revusiran program, stock plunges. Nat. Biotechnol. 34, 1213–1214 (2016).

    Article  CAS  Google Scholar 

  6. Huggett, B. America's drug problem. Nat. Biotechnol. 34, 1231–1241 (2017).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Chris Morrison is a freelance writer based in Yardley, Pennsylvania, USA, and,

    Chris Morrison

  2. Riku Lähteenmäki is a freelance writer working in Turku, Finland.,

    Riku Lähteenmäki

Authors
  1. Chris Morrison
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Riku Lähteenmäki
    View author publications

    You can also search for this author in PubMed Google Scholar

Supplementary information

Supplementary Text and Figures

Supplementary Table 1 (XLS 212 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Morrison, C., Lähteenmäki, R. Public biotech in 2016—the numbers. Nat Biotechnol 35, 623–629 (2017). https://doi.org/10.1038/nbt.3917

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.3917

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation